of several HER2-targeted agents, including monoclonal antibodies, tyrosine-kinase inhibitors and antibody–drug conjugates, has increased cure rates in patients with early stage HER2-positive (HER2+) breast cancer and substantially improved survival for patients with advanced-stage HER2+ breast cancer. ...
In this Review, we describe key steps in the development of the modern paradigm for the treatment of HER2-positive advanced-stage breast cancer, including selecting and sequencing new-generation HER2-targeted therapies, and summarize efficacy and safety outcomes from pivotal studies. We then outline ...
September 14, 2021 Author(s): OncLive Staff In the second segment, Dr Pegram and colleagues discuss the clinical implications of the data from select trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer....
Matthew,James,Ellis - 《J Natl Cancer Inst》 被引量: 3发表: 2014年 Early Stage HER2 Positive Breast Cancers Not Achieving A pCR From Neoadjuvant Trastuzumab Or Pertuzumab Based Regimens Have An Immunosuppressive Phenotype Early stage HER2-positive breast cancers not achieving a pCR From neoadjuvant...
Dr Ian Krop will talk about a case of a patient with early-stage HER2-positive breast cancer.Ian Krop, MD, PhD: Thanks, Hope. I think I have a case that’s interesting, both because it presents some good medical oncology discussion points but also because it presents some good pathology...
De-intensif i cation of therapy for early-stage HER2-positive breast cancerDe-intensif i cation of breast cancer treatment is a laudable goal. Fewer aggressive breast and axillary surgeries are now needed to achieve excellent out-comes, and genomic assays can help to identify patients in whom ad...
Transcript:Adam M. Brufsky, MD, PhD:So, let’s move on to HER2-positive breast cancer. And I think that the questions that have been asked in the last couple of months to years with this is, what do we do with the triple-positive, the HER2-positive, and ER-positive group of patie...
Chemotherapy is commonly recommended during this stage, and hormonal therapy may be used for those with hormone-receptor-positive cancer. Targeted therapy may also be used for people with cancers that have too many HER2 proteins or other characteristics. ...
Objective To examine the prognostic ability of TILs and immune-related gene expression signatures, alone and in combination, to predict pCR and EFS in patients with early-stage ERBB2/HER2-positive breast cancer treated in 2 clinical trials. Design, Setting, and Participants In this prognostic study...
Background: Very effective trastuzumab-based primary systemic therapy (PST) can be proposed for conservative surgery purpose to human epidermal growth factor receptor 2 (HER2)-positive breast cancer (HER2+BC). Long-term follow-up (LTFU) warrants further data.S. Guiu...